Publications by authors named "Edward Fiets"

Claim this Profile
D
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study.
Jonathan E Knikman, Mirjam de With, Niels Heersche, Marta Lopez-Yurda, Arnold Baars, Edward Fiets

Eur J Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial.
Berend J van der Wilk, Ben M Eyck, Bas P L Wijnhoven, Sjoerd M Lagarde, Camiel Rosman, W Edward Fiets

Lancet Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the clinical benefit of systemic anti-cancer treatments in the Netherlands: The impact of different thresholds for effectiveness.
Brenda Leeneman, Nicolas S H Xander, W Edward Fiets, Wouter K de Jong, Nathalie E M Uyl

Eur J Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands.
Nicolas S H Xander, W Edward Fiets, Carin A Uyl-de Groot

Front Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
Maartje W Rohaan, Troels H Borch, Joost H van den Berg, Özcan Met, Rob Kessels, W Edward Fiets

N Engl J Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence.
Janneke C Ham, Esther van Meerten, W Edward Fiets, Laurens V Beerepoot, Frank J F Jeurissen

Head Neck· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prophylactic antibiotics reduce hospitalisations and cost in locally advanced head and neck cancer patients treated with chemoradiotherapy: A randomised phase 2 study.
Janneke C Ham, Chantal M Driessen, Mathijs P Hendriks, Edward Fiets, Bas Kreike

Eur J Cancer· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mannose binding lectin and prediction of risk for chemotherapy induced febrile neutropenia in patients with a solid tumor.
Cynthia Epskamp, Jeannette A Goudzwaard, Edward Fiets, Johanna M Zuetenhorst, Marco B Polee

Cancer Invest· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.
Eline Boon, Wim van Boxtel, Jan Buter, Robert J Baatenburg de Jong, Robert J J van Es, Edward Fiets

Head Neck· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.
Sander Kelderman, Bianca Heemskerk, Harm van Tinteren, Rob R H van den Brom, Geke A P Hospers, Edward Fiets

Cancer Immunol Immunother· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients.
Maxime Look, Wim van Putten, Michael Duffy, Nadia Harbeck, Ib Jarle Christensen, W Edward Fiets

Thromb Haemost· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
Maxime P Look, Wim L J van Putten, Michael J Duffy, Nadia Harbeck, Ib Jarle Christensen, W Edward Fiets

J Natl Cancer Inst· January 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis